
NewAmsterdam (NAMS) via Frazier Lifesciences (FLAC) deck
NewAmsterdam Pharma is a late clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases.
This post is for subscribers only
SubscribeAlready have an account? Log in